TheDrug Industry Documents Archive (DIDA) is a digital archive ofpharmaceutical industry documents created and maintained by theUniversity of California, San Francisco,Library and Center for Knowledge Management. DIDA is a part of the larger UCSFIndustry Documents Library which includes theTruth Tobacco Industry Documents. The archive contains documents about pharmaceutical industryclinical trials, publication of study results, pricing,marketing, relations with physicians and drug company involvement incontinuing medical education.

Most of the documents on DIDA were made public as a result of lawsuits against pharmaceutical companiesParke-Davis,Warner-Lambert,Pfizer,Merck & Co.,Wyeth andAbbott Labs, among others. DIDA was founded in 2005 with the support of a gift by Thomas Greene, the attorney forDavid Franklin, whistleblower in United States ex rel. Franklin v. Parke-Davis, the case from which the first documents in the archive originated.^[1]

Researchers as well as students, journalists, and the general public, use the archive to investigate the ways pharmaceutical companies market their products. TheUCSF_Library created this digital archive in an attempt to facilitate further research into the drug industry's practice of establishing close links with the medical community which has been shown to influence scientific research, drug approval, prescription practices, and ultimately, consumer health.^[2][3]

DIDA contains:

• internal pharmaceutical company documents
• correspondence between drug companies and physicians, researchers and educational institutions
• regulatory and legal documents
• court filings
• depositions
• expert reports
• internal University documents

Documents come from a variety of sources including:

• Lawsuits againstMerck & Co. regarding the marketing and use ofVioxx
• The landmarkwhistleblower case involving Neurontin (gabapentin) andoff-label marketing:United States of America ex rel. David Franklin vs. Parke-Davis, Division of Warner-Lambert/Pfizer
• Investigations intoconflict of interest and academic institutions by theUS Senate Finance Committee, headed byCharles Grassley (R-Iowa)
• Investigations into the marketing of Vioxx to physicians by theUnited States House Committee on Oversight and Government Reform, headed byHenry A. Waxman
• Antitrust litigation involving Abbott Labs and theirHIV/AIDS drugNorvir
• Lawsuits againstWyeth for the unethical promotion of the hormone replacement drugPremarin to women. Wyeth paidmedical ghostwriters to author journal articles about the drug.

• Hill, K.; et al. (2008). "The ADVANTAGE Seeding Trial: A Review of Internal Documents".Annals of Internal Medicine.149 (4):251–258.doi:10.7326/0003-4819-149-4-200808190-00006.PMID 18711155.
• Landefeld, S; Steinman, M. (January 2009). "The Neurontin Legacy - Marketing through Misinformation".NEJM.360 (2):103–6.doi:10.1056/nejmp0808659.PMID 19129523.
• Waxman, HA.Memorandum to the Democratic Members of the Government Reform Committee: The marketing of Vioxx to physicians. May 5, 2005. Committee on Government Reform Minority Office, United States House of Representatives.

• Official website

• Pharmaceutical industry
• American digital libraries
• Business and industry archives
• University of California, San Francisco

• Official website different in Wikidata and Wikipedia